永安药业：2025年净利润预降56.21%-70.56%

Core Viewpoint - Yong'an Pharmaceutical announced an expected decline in net profit attributable to shareholders for 2025, forecasting a range of 18.19 million to 27.05 million yuan, representing a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -2.88 million and -1.55 million yuan, indicating a decline of 105.80% to 110.77% year-on-year [1] - The decline in performance is primarily attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the production and sales prices of the main product, taurine [1]